FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209696856> ?p ?o ?g. }

• W3209696856 endingPage "5828" @default.
• W3209696856 startingPage "5809" @default.
• W3209696856 abstract "Spinal muscular atrophy (SMA) is a rare, genetic neuromuscular disorder caused by deletion/mutation of the survival motor neuron 1 gene, characterized by progressive loss of motor neurons, resulting in increasing muscular weakness, deteriorating motor function, and, in its most severe form, death before 2 years. Nusinersen, an antisense oligonucleotide that increases expression of the functional SMN protein, was approved for SMA by US and European regulatory agencies in 2016 and 2017, respectively. The indicated regimen requires intrathecal injections every 4 months, following the first four injections during the loading phase. Adherence is integral to treatment success. Adherence to nusinersen may pose particular challenges as most patients with SMA are young children who require complex multidisciplinary care (including ongoing intrathecal treatment administration and potential specialized anesthetic and surgical procedures) at specialized centers. However, real-world data on adherence to nusinersen are limited.We conducted a retrospective claims database analysis from December 23, 2016, to November 20, 2019, to study nusinersen adherence and discontinuation/persistence in US patients with SMA types 1-3 who completed the loading phase, and to determine the impact of non-adherence or treatment discontinuation on SMA-related comorbidities, health care resource utilization (HCRU), and costs.We identified 23 patients with SMA type 1, 41 patients with SMA type 2, and 260 patients with SMA type 3 who had completed the loading phase. Deviations from the indicated nusinersen treatment schedule were frequent in real-world usage, with most patients receiving ≥1 dose outside the scheduled interval. Across SMA types, non-adherent patients were more likely to have had SMA-related comorbidities (e.g., feeding difficulties, dyspnea and respiratory anomalies, and muscle weakness) and greater HCRU. Persistence rates 12 months after treatment initiation for patients with SMA types 1, 2, and 3 were 55.2%, 42.4%, and 54.6%, respectively. Patients who discontinued nusinersen and those who did not had generally similar comorbidity profiles. Discontinuation was associated with greater health care costs across SMA types.Our analysis of claims data indicated that discontinuation and non-adherence to nusinersen treatment were prevalent, and associated with greater frequency of comorbidities, greater HCRU, and increased costs for patients." @default.
• W3209696856 created "2021-11-08" @default.
• W3209696856 creator A5013167675 @default.
• W3209696856 creator A5023788329 @default.
• W3209696856 creator A5042307748 @default.
• W3209696856 creator A5053962996 @default.
• W3209696856 creator A5062639951 @default.
• W3209696856 creator A5066720336 @default.
• W3209696856 creator A5073850552 @default.
• W3209696856 creator A5078295037 @default.
• W3209696856 creator A5080691892 @default.
• W3209696856 date "2021-10-28" @default.
• W3209696856 modified "2023-10-05" @default.
• W3209696856 title "Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis" @default.
• W3209696856 cites W15348943 @default.
• W3209696856 cites W2052810066 @default.
• W3209696856 cites W2071346782 @default.
• W3209696856 cites W2094108169 @default.
• W3209696856 cites W2135785083 @default.
• W3209696856 cites W2143197369 @default.
• W3209696856 cites W2148071380 @default.
• W3209696856 cites W2155441883 @default.
• W3209696856 cites W2157788227 @default.
• W3209696856 cites W2167256464 @default.
• W3209696856 cites W2324878797 @default.
• W3209696856 cites W2518437995 @default.
• W3209696856 cites W2574742175 @default.
• W3209696856 cites W2602046865 @default.
• W3209696856 cites W2743439262 @default.
• W3209696856 cites W2746562707 @default.
• W3209696856 cites W2765483614 @default.
• W3209696856 cites W2789114047 @default.
• W3209696856 cites W2790318238 @default.
• W3209696856 cites W2804732925 @default.
• W3209696856 cites W2890315635 @default.
• W3209696856 cites W2906546838 @default.
• W3209696856 cites W2964116403 @default.
• W3209696856 cites W3094687645 @default.
• W3209696856 doi "https://doi.org/10.1007/s12325-021-01938-w" @default.
• W3209696856 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8552979" @default.
• W3209696856 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34713391" @default.
• W3209696856 hasPublicationYear "2021" @default.
• W3209696856 type Work @default.
• W3209696856 sameAs 3209696856 @default.
• W3209696856 citedByCount "8" @default.
• W3209696856 countsByYear W32096968562022 @default.
• W3209696856 countsByYear W32096968562023 @default.
• W3209696856 crossrefType "journal-article" @default.
• W3209696856 hasAuthorship W3209696856A5013167675 @default.
• W3209696856 hasAuthorship W3209696856A5023788329 @default.
• W3209696856 hasAuthorship W3209696856A5042307748 @default.
• W3209696856 hasAuthorship W3209696856A5053962996 @default.
• W3209696856 hasAuthorship W3209696856A5062639951 @default.
• W3209696856 hasAuthorship W3209696856A5066720336 @default.
• W3209696856 hasAuthorship W3209696856A5073850552 @default.
• W3209696856 hasAuthorship W3209696856A5078295037 @default.
• W3209696856 hasAuthorship W3209696856A5080691892 @default.
• W3209696856 hasBestOaLocation W32096968561 @default.
• W3209696856 hasConcept C114614502 @default.
• W3209696856 hasConcept C126322002 @default.
• W3209696856 hasConcept C141071460 @default.
• W3209696856 hasConcept C161921814 @default.
• W3209696856 hasConcept C167135981 @default.
• W3209696856 hasConcept C1862650 @default.
• W3209696856 hasConcept C187212893 @default.
• W3209696856 hasConcept C2776356578 @default.
• W3209696856 hasConcept C2778558090 @default.
• W3209696856 hasConcept C2778715236 @default.
• W3209696856 hasConcept C2779134260 @default.
• W3209696856 hasConcept C2780247198 @default.
• W3209696856 hasConcept C2781413609 @default.
• W3209696856 hasConcept C33923547 @default.
• W3209696856 hasConcept C71924100 @default.
• W3209696856 hasConceptScore W3209696856C114614502 @default.
• W3209696856 hasConceptScore W3209696856C126322002 @default.
• W3209696856 hasConceptScore W3209696856C141071460 @default.
• W3209696856 hasConceptScore W3209696856C161921814 @default.
• W3209696856 hasConceptScore W3209696856C167135981 @default.
• W3209696856 hasConceptScore W3209696856C1862650 @default.
• W3209696856 hasConceptScore W3209696856C187212893 @default.
• W3209696856 hasConceptScore W3209696856C2776356578 @default.
• W3209696856 hasConceptScore W3209696856C2778558090 @default.
• W3209696856 hasConceptScore W3209696856C2778715236 @default.
• W3209696856 hasConceptScore W3209696856C2779134260 @default.
• W3209696856 hasConceptScore W3209696856C2780247198 @default.
• W3209696856 hasConceptScore W3209696856C2781413609 @default.
• W3209696856 hasConceptScore W3209696856C33923547 @default.
• W3209696856 hasConceptScore W3209696856C71924100 @default.
• W3209696856 hasIssue "12" @default.
• W3209696856 hasLocation W32096968561 @default.
• W3209696856 hasLocation W32096968562 @default.
• W3209696856 hasLocation W32096968563 @default.
• W3209696856 hasLocation W32096968564 @default.
• W3209696856 hasOpenAccess W3209696856 @default.
• W3209696856 hasPrimaryLocation W32096968561 @default.
• W3209696856 hasRelatedWork W2121965889 @default.
• W3209696856 hasRelatedWork W2143197369 @default.
• W3209696856 hasRelatedWork W2587100982 @default.

• next